These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18231580)

  • 21. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.
    Spring MD; Cummings JF; Ockenhouse CF; Dutta S; Reidler R; Angov E; Bergmann-Leitner E; Stewart VA; Bittner S; Juompan L; Kortepeter MG; Nielsen R; Krzych U; Tierney E; Ware LA; Dowler M; Hermsen CC; Sauerwein RW; de Vlas SJ; Ofori-Anyinam O; Lanar DE; Williams JL; Kester KE; Tucker K; Shi M; Malkin E; Long C; Diggs CL; Soisson L; Dubois MC; Ballou WR; Cohen J; Heppner DG
    PLoS One; 2009; 4(4):e5254. PubMed ID: 19390585
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.
    Sheehy SH; Duncan CJ; Elias SC; Choudhary P; Biswas S; Halstead FD; Collins KA; Edwards NJ; Douglas AD; Anagnostou NA; Ewer KJ; Havelock T; Mahungu T; Bliss CM; Miura K; Poulton ID; Lillie PJ; Antrobus RD; Berrie E; Moyle S; Gantlett K; Colloca S; Cortese R; Long CA; Sinden RE; Gilbert SC; Lawrie AM; Doherty T; Faust SN; Nicosia A; Hill AV; Draper SJ
    Mol Ther; 2012 Dec; 20(12):2355-68. PubMed ID: 23089736
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum.
    Behet MC; Foquet L; van Gemert GJ; Bijker EM; Meuleman P; Leroux-Roels G; Hermsen CC; Scholzen A; Sauerwein RW
    Malar J; 2014 Apr; 13():136. PubMed ID: 24708526
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: a case-control study.
    Dobaño C; Ubillos I; Jairoce C; Gyan B; Vidal M; Jiménez A; Santano R; Dosoo D; Nhabomba AJ; Ayestaran A; Aguilar R; Williams NA; Díez-Padrisa N; Lanar D; Chauhan V; Chitnis C; Dutta S; Gaur D; Angov E; Asante KP; Owusu-Agyei S; Valim C; Gamain B; Coppel RL; Cavanagh D; Beeson JG; Campo JJ; Moncunill G
    BMC Med; 2019 Aug; 17(1):157. PubMed ID: 31409398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunization of Malaria-Preexposed Volunteers With PfSPZ Vaccine Elicits Long-Lived IgM Invasion-Inhibitory and Complement-Fixing Antibodies.
    Zenklusen I; Jongo S; Abdulla S; Ramadhani K; Lee Sim BK; Cardamone H; Flannery EL; Nguyen T; Fishbaugher M; Steel RWJ; Betz W; Carmago N; Mikolajczak S; Kappe SHI; Hoffman SL; Sack BK; Daubenberger C
    J Infect Dis; 2018 Apr; 217(10):1569-1578. PubMed ID: 29438525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transcriptional changes induced by candidate malaria vaccines and correlation with protection against malaria in a human challenge model.
    Dunachie S; Berthoud T; Hill AV; Fletcher HA
    Vaccine; 2015 Sep; 33(40):5321-31. PubMed ID: 26256523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
    Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
    Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
    Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
    Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A human Phase I/IIa malaria challenge trial of a polyprotein malaria vaccine.
    Porter DW; Thompson FM; Berthoud TK; Hutchings CL; Andrews L; Biswas S; Poulton I; Prieur E; Correa S; Rowland R; Lang T; Williams J; Gilbert SC; Sinden RE; Todryk S; Hill AV
    Vaccine; 2011 Oct; 29(43):7514-22. PubMed ID: 21501642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity.
    Chuang I; Sedegah M; Cicatelli S; Spring M; Polhemus M; Tamminga C; Patterson N; Guerrero M; Bennett JW; McGrath S; Ganeshan H; Belmonte M; Farooq F; Abot E; Banania JG; Huang J; Newcomer R; Rein L; Litilit D; Richie NO; Wood C; Murphy J; Sauerwein R; Hermsen CC; McCoy AJ; Kamau E; Cummings J; Komisar J; Sutamihardja A; Shi M; Epstein JE; Maiolatesi S; Tosh D; Limbach K; Angov E; Bergmann-Leitner E; Bruder JT; Doolan DL; King CR; Carucci D; Dutta S; Soisson L; Diggs C; Hollingdale MR; Ockenhouse CF; Richie TL
    PLoS One; 2013; 8(2):e55571. PubMed ID: 23457473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Liver-Directed AAV8 Booster Vaccine Expressing
    Shahnaij M; Iyori M; Mizukami H; Kajino M; Yamagoshi I; Syafira I; Yusuf Y; Fujiwara K; Yamamoto DS; Kato H; Ohno N; Yoshida S
    Front Immunol; 2021; 12():612910. PubMed ID: 34248928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel sporozoite-based ELISpot assay to assess frequency of parasite-specific B cells after vaccination with irradiated sporozoites.
    Atre T; Robinson TM; Savransky T; Dutta S; Epstein JE; Bergmann-Leitner ES
    Malar J; 2019 May; 18(1):186. PubMed ID: 31142328
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A randomized placebo-controlled phase Ia malaria vaccine trial of two virosome-formulated synthetic peptides in healthy adult volunteers.
    Genton B; Pluschke G; Degen L; Kammer AR; Westerfeld N; Okitsu SL; Schroller S; Vounatsou P; Mueller MM; Tanner M; Zurbriggen R
    PLoS One; 2007 Oct; 2(10):e1018. PubMed ID: 17925866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 1 trial of PfCP2.9: an AMA1/MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria.
    Malkin E; Hu J; Li Z; Chen Z; Bi X; Reed Z; Dubovsky F; Liu J; Wang Q; Pan X; Chen T; Giersing B; Xu Y; Kang X; Gu J; Shen Q; Tucker K; Tierney E; Pan W; Long C; Cao Z
    Vaccine; 2008 Dec; 26(52):6864-73. PubMed ID: 18930094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Development of Whole Sporozoite Vaccines for
    Itsara LS; Zhou Y; Do J; Grieser AM; Vaughan AM; Ghosh AK
    Front Immunol; 2018; 9():2748. PubMed ID: 30619241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody responses to Plasmodium falciparum sporozoite-, liver- and blood-stage synthetic peptides in migrant and autochthonous populations in malaria endemic areas.
    Ferreira-da-Cruz MF; Deslandes DC; Oliveira-Ferreira J; Montenegro-James S; Tartar A; Druilhe P; Daniel-Ribeiro CT
    Parasite; 1995 Mar; 2(1):23-9. PubMed ID: 9137641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.
    Biswas S; Choudhary P; Elias SC; Miura K; Milne KH; de Cassan SC; Collins KA; Halstead FD; Bliss CM; Ewer KJ; Osier FH; Hodgson SH; Duncan CJ; O'Hara GA; Long CA; Hill AV; Draper SJ
    PLoS One; 2014; 9(9):e107903. PubMed ID: 25254500
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity.
    Bijker EM; Bastiaens GJ; Teirlinck AC; van Gemert GJ; Graumans W; van de Vegte-Bolmer M; Siebelink-Stoter R; Arens T; Teelen K; Nahrendorf W; Remarque EJ; Roeffen W; Jansens A; Zimmerman D; Vos M; van Schaijk BC; Wiersma J; van der Ven AJ; de Mast Q; van Lieshout L; Verweij JJ; Hermsen CC; Scholzen A; Sauerwein RW
    Proc Natl Acad Sci U S A; 2013 May; 110(19):7862-7. PubMed ID: 23599283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of influenza immunity and virosomal-formulated synthetic peptide to cellular immune responses in a phase I subunit malaria vaccine trial.
    Peduzzi E; Westerfeld N; Zurbriggen R; Pluschke G; Daubenberger CA
    Clin Immunol; 2008 May; 127(2):188-97. PubMed ID: 18337175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.